Join now & save up to 80% on medication

JOIN NOW
Select Language:

Join now and save 80% on medication

Register/Login
New here? Get 10% off with code WELCOME10

Nesina (Alogliptin): Uses, Side Effects and Dosage

Share Post:

What is Nesina (Alogliptin)?

Alogliptin is a medication that is indicated for people with type 2 diabetes who are not achieving sufficient levels of glycemic control for optimal health. An oral antidiabetic drug, it can be used as an adjunct to a good diet and plenty of exercise for type 2 diabetics who cannot use metformin due to contraindications or intolerance.

When diet and exercise alone do not provide adequate glycemic control, alogliptin can be used in combination with metformin, sulfonylureas, pioglitazone, and/or insulin.

The alogliptin brand name is Nesina. The Nesina drug class is dipeptidyl peptidase-4 inhibitor (gliptin). It was developed by Syrrx, which was acquired by Takeda Pharmaceutical Company in 2005. The drug was approved for use by the Food and Drug Administration (FDA) in January 2013.

What is it used for?

Nesina is used by type 2 diabetics to achieve stable blood glucose levels, especially when other antidiabetic agents, like metformin and/or sulfonylureas, do not elicit the desired level of glucose stability.

This medication is not established for safety or efficacy in geriatric patients (>65 years of age) or pediatric patients (<18 years), so use of Nesina or a Nesina generic is not recommended in these groups.

How to take Alogliptin

It is necessary to titrate and closely monitor the dosage of Nesina based on the patient’s renal function and performance. A full assessment of renal function is highly recommended before a patient embarks on therapy with Nesina. These tests should be repeated at regular intervals during treatment to establish an efficacy regime.

No dosage adjustment is generally necessary based on the age of the patient, however dosing should be conservatively administered in patients of advanced age because of the possibility of renal failure.

Nesina side effects

Nesina was generally well-tolerated in controlled clinical studies. Serious side effects were rare. As with any diabetes-controlling medication, Nesina can induce a potentially dangerous state called hypoglycemia. It is unlikely to cause weight gain and the risk of hypoglycemia is low.

Common side effects

  • Headache
  • Upper respiratory tract infection
  • Nasopharyngitis

Severe side effects

  • Hypoglycemia
  • Hypersensitivity reactions
  • Renal impairment

Dosage

Nesina can be administered with or without food and it is taken as a once-daily tablet. The recommended starting dosage of Alogliptin is 25mg daily.

For a patient with moderate renal impairment, the dose is 12.5mg once daily. For severe renal impairment and end-stage renal disease, the dose is 6.25mg once daily.

Doctor’s Recommendation

Do not use Nesina if you have had a severe allergic reaction to alogliptin or its ingredients, as it may cause serious side effects. Inform your doctor if you have kidney or heart failure history before starting Nesina. Contact your doctor right away if you experience increased shortness of breath, trouble breathing while lying down, rapid weight gain, swelling in your legs or ankles, or unusual tiredness. Nesina can also cause severe pancreatitis, so let your doctor know if you have had pancreatitis, liver or kidney problems, high triglycerides, gallstones, or a history of alcohol use.

Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.

Medically Reviewed

Profile image of Lalaine Cheng

Medically Reviewed By Lalaine ChengA dedicated medical practitioner with a Master’s degree in Public Health, specializing in epidemiology with a profound focus on overall wellness and health, brings a unique blend of clinical expertise and research acumen to the forefront of healthcare. As a researcher deeply involved in clinical trials, I ensure that every new medication or product satisfies the highest safety standards, giving you peace of mind, individuals and healthcare providers alike. Currently pursuing a Ph.D. in Biology, my commitment to advancing medical science and improving patient outcomes is unwavering.

Profile image of CDI Staff Writer

Written by CDI Staff WriterOur internal team are experts in many subjects. on October 24, 2019

Related Products

Ozempic
  • In Stock
  • Express Shipping
New Lower Price
Mounjaro Vial
  • In Stock
  • Express Shipping
Rybelsus
  • In Stock
  • Express Shipping
Bulk Savings
Humalog Vial
  • In Stock
  • Express Shipping

Related Articles

Diabetes, Diabetes Tests,
Join the Cause: American Diabetes Month 2025

Every November, millions of Americans come together to shine a light on one of the country’s most pressing health challenges — diabetes. American Diabetes Month is more than just a…

Read More
Diabetes, Type 2
Orforglipron vs Rybelsus: Which Is More Effective?

According to the International Diabetes Federation (IDF), around 589 million adults aged 20–79 are living with diabetes globally. This marks the need for immediate medical action and treatment. Fortunately, with…

Read More
Diabetes, Diabetes Supplies,
How to Travel with Ozempic: Keep Your Dose Effective

Vacations, business trips, and weekend getaways shouldn’t interfere with your health routine. For people using Ozempic, planning ahead is key to keeping your medication safe and effective while on the…

Read More
Diabetes, Diabetes Supplies,
Xultophy Side Effects: What to Expect and Watch For

Xultophy is a prescription medication that combines two active ingredients, insulin degludec (a long-acting insulin) and liraglutide (a GLP-1 receptor agonist), to help manage blood sugar in adults with type…

Read More